Research / Dog NGAL ELISA


Cat.No. KIT 043

An ELISA for the in vitro determination of dog NGAL in urine, plasma, serum, tissue extracts or culture media.
Target Dog NGAL (Neutrophil Gelatinase-Associated Lipocalin
Sample Type Dog urine, plasma or serum, tissue extracts or culture media
Cross reaction None
Numbers of tests 96 wells - 40 test in duplicate
Sample vol needed 10 µl
Dilution guideline NA
Assay range 4-400 pg/mL
Limit of Detection 0.56 pg/mL
Assay time <4 hours
Result type Quantitative (pg/mL)
Application For Research Use Only (RUO)

Dog NGAL - a marker for nephrotoxicity and kidney damage in pre-clinical trials

With the Dog NGAL ELISA Kit, urine, plasma or serum samples can be analyzed in a standard laboratory with conventional ELISA equipment. All components are stored at 4°C and all incubations are performed at room temperature. The kit contains ready-to-use reagents and a pre-coated 96-well ELISA plate, which greatly reduces the hands-on time. The simple test protocol permits good reproducibility with a total assay time under 4 hours.

Kit features

  • Highly reproducible and easy to use
    • Ready-to-use working solutions
    • Ready-to-use calibrators
    • Pre-coated 96-well ELISA plate
    • All incubations performed at room temperature
  • Easy storage
    • All components are stored at 4°C
  • Requires only standard ELISA equipment


Dogs provide additional information in the study of kidney function, surgical procedures and treatment in relation to human disease, and canine studies continue to be important in drug development. The dog NGAL ELISA test is non-invasive, and gives an early indication of kidney damage, uses little sample and is easy to perform. NGAL measurement in dogs may prove to be of considerable value in the preclinical evaluation of new pharmaceutical products, as it is much cheaper and easier to perform than microscopic examination of the kidney, which has hitherto been the usual procedure.

The test can potentially be used to measure drug efficacy in the development of new treatments for kidney damage, to assess safety or nephrotoxic side effects of new drugs, and can be used in basic research on kidney injury and kidney diseases, e.g. in the folowing settings:

  • Discovery
  • Research and development
  • Pre-clinical phase